<unk>  <unk>  is life-threatening leukemia in which malignant megakaryoblasts proliferate abnormally and injure various tissues. Megakaryoblasts are the most immature precursor cells in a platelet-forming lineage; they mature to promegakaryocytes and, ultimately, megakaryocytes which cells shed membrane-enclosed particles, i.e. platelets, into the circulation. Platelets are critical for the normal clotting of blood. While malignant megakaryoblasts usually are the predominant proliferating and tissue-damaging cells, their similarly malignant descendants, promegakaryocytes and megakaryocytes, are variable contributors to the malignancy.<unk>  is commonly regarded as a subtype of acute myeloid leukemia (AML). More formally, it is classified under the AML-M7 category of the French-American-British classification and by the World Health Organization of 2016 in the AML-Not Otherwise Specified subcategory.<unk>  falls into three distinct groups which differ in underlying causes, ages of presentation, responses to therapy, and prognoses. These groups are:<unk>  occurring in young children with Down syndrome, i.e. DS-AMKL;<unk>  occurring in children who do not have Down syndrome, i.e. non-DS-AMKL (also termed pediatric<unk>  or pediatric<unk> ; and<unk>  occurring in non-DS adults, i.e. adult-AMKL.<unk> , while rare, is the most common form of AML in DS-AMKL, occurring ~500-fold more commonly in Down syndrome children than in children without Down syndrome; non-DS-AMKL and adult-AMLK are rare, accounting for <1% of all individuals diagnosed as in the AML-M7 category of leukemia.
Acute megakaryoblastic leukemia
Prolymphocytic leukemia
Acute myeloblastic leukemia with maturation
Acute erythroid leukemia
Myeloid leukemia
Acute myeloblastic leukemia without maturation
Acute myelomonocytic leukemia
Acute promyelocytic leukemia